Publication details
Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | British Journal of Dermatology |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1111/bjd.13717 |
| Field | Other medical specializations |
| Keywords | LINKED-IMMUNOSORBENT-ASSAY; INDIRECT IMMUNOFLUORESCENCE; TOPICAL CORTICOSTEROIDS; MYCOPHENOLATE-MOFETIL; PLASMA-EXCHANGE; DIAGNOSIS; DISEASES; MULTICENTER; AZATHIOPRINE; ACQUISITA |
| Description | Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients, bullae may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. Our consensus for the treatment of bullous pemphigoid has been developed under the guidance of the European Dermatology Forum in collaboration with the European Academy of Dermatology and Venereology. It summarizes evidence-based and expert-based recommendations. |